{"id":"sm03","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Immunosuppression-related events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SM03 binds to CD40 ligand, a key costimulatory molecule involved in T cell-dependent B cell activation and immune cell interactions. By blocking CD40L, the drug suppresses pathogenic immune responses and reduces inflammatory cytokine production. This mechanism is intended to treat autoimmune and inflammatory conditions where CD40L-mediated signaling drives disease pathology.","oneSentence":"SM03 is a monoclonal antibody that targets CD40 ligand (CD40L) to modulate immune responses and reduce inflammatory activation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:53:08.584Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus (SLE)"},{"name":"Autoimmune conditions"}]},"trialDetails":[{"nctId":"NCT04704492","phase":"PHASE1","title":"A Study of the Pharmacokinetics and Safety of SM03 in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"SinoMab BioScience Ltd","startDate":"2012-08-14","conditions":"Rheumatoid Arthritis","enrollment":8},{"nctId":"NCT04312815","phase":"PHASE3","title":"A Study Assessing the Efficacy and Safety of SM03 in Patients With Active Rheumatoid Arthritis Receiving MTX","status":"UNKNOWN","sponsor":"SinoMab BioScience Ltd","startDate":"2017-12-28","conditions":"Rheumatoid Arthritis(RA)","enrollment":510},{"nctId":"NCT04192617","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of SM03 in Patients With Rheumatoid Arthritis Receiving Methotrexate","status":"COMPLETED","sponsor":"SinoMab BioScience Ltd","startDate":"2014-12-31","conditions":"Rheumatoid Arthritis","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SM03","genericName":"SM03","companyName":"SinoMab BioScience Ltd","companyId":"sinomab-bioscience-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SM03 is a monoclonal antibody that targets CD40 ligand (CD40L) to modulate immune responses and reduce inflammatory activation. Used for Systemic lupus erythematosus (SLE), Autoimmune conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}